Microlyte Matrix
Commercial- Indications
- Chronic wounds
Company intelligence / Profile preview
Imbed Biosciences has commercialized its Microlyte Matrix product line for advanced wound care. The company’s products are FDA-cleared medical devices used in the management of burns, chronic wounds, and surgical wounds. Over 100,000 units have been sold internationally with demonstrated clinical utility in improving patient outcomes and reducing costs. The company recently received FDA clearance for Microlyte Ag/Lidocaine—the first antimicrobial wound dressing integrating lidocaine for pain management—and continues to expand globally.
2 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Imbed Biosciences.